Physician profile

Iris Diaz

Family · Estero, FL

NPI 1972202612

$680.91

in general payments reported to CMS, 2019-2025

4 companies · $681 in 2025

The $681 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$680.91

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $271.22 2025 Ams 700, Axonics, Accutrac
Teleflex LLC $137.38 2025 Urolift
Procept Biorobotics Corporation $136.77 2025
Endo USA, INC. $135.54 2025 Xiaflex

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Iris Diaz

$680.91

in general payments reported 2019-2025

Years
2025
Top company
Boston Scientific Corporation
Context
The $681 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).

https://glasscript.com/doctor/11482917/iris-diaz

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.